Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy – Blood Journals Portfolio
A recent study published by Blood Journals Portfolio (May 2024) available here demonstrates that recombinant ADAMTS13 (rADAMTS13) offers significantly more efficient ADAMTS13 replacement than traditional plasma infusions in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
This finding marks a critical step forward in targeted therapy for patients with severe ADAMTS13 deficiency, a condition that leads to life-threatening microangiopathic hemolytic anemia and thrombocytopenia. Unlike plasma, which delivers ADAMTS13 in variable and limited concentrations, recombinant formulations offer predictable pharmacokinetics, higher bioavailability, and eliminate the risks associated with plasma-derived products, including allergic reactions and pathogen transmission.
These results underscore the potential of rADAMTS13 to become the standard of care in managing cTTP, improving prophylactic and acute-phase treatment outcomes.
Blood Journals Portfolio shared on X:
“Recombinant ADAMTS13 can supply ADAMTS13 more efficiently than plasma to patients with congenital thrombotic thrombocytopenic purpura.”
Title: Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data
Autors: Kazuya Sakai, Atsushi Hamamura, Yoshiko Yoshimura, Miyuki Abe, Yoshiyuki Ogawa, Kazuki Tanaka, Norimichi Hattori, Tazuko Tokugawa, Rie Kanai, Fumiyoshi Ikejiri, Masahiro Takeyama, Teruhisa Taoka, Naoki Fujita, Minoru Kanaya, Katsuyoshi Koh, Hiroshi Shiragami, Hidekazu Azumi, Kenki Saito, Masanori Matsumoto
See more in-depth professional insights at Hemostasis Today, where we bring you the latest advances in thrombosis, hemostasis, and rare bleeding disorders.
-
Jun 19, 2025, 03:39ASH Recognizes 11 Hematologists for Transformative Contributions to Blood Disorder Research
-
Jun 17, 2025, 10:3025 Posts Not to Miss from EHA 2025
-
Jun 17, 2025, 05:10Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy - Blood Journals Portfolio
-
Jun 16, 2025, 17:00Hypoxia and Emergency Caesarean Deliveries Worsen Postpartum Outcomes in Sickle Cell Disease: New Insights from Perinatal Hemostasis Research
-
Jun 16, 2025, 10:42Jorge Cortes: The First Issue of Blood Global Hematology is Out
-
Jun 18, 2025, 15:49Abdul Mannan: Laboratory Alert - DOAC Interference in Heparin Monitoring
-
Jun 18, 2025, 08:19William Aird: Thrombocytosis - Know the difference, think before you refer
-
Jun 16, 2025, 18:24Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
-
Jun 16, 2025, 16:24Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
-
Jun 15, 2025, 09:32Silent Threat: Underrated Risk of Thrombosis in IBD Outpatients Revealed by New Data - Thrombosis Update
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 18, 2025, 10:30Join "Where Cardiologists and Hematologists Meet" Session Organized by ESC and EHA
-
Jun 18, 2025, 09:01Nihar Desai: A 35 Year Old Man Presents with High Grade Fever...
-
Jun 17, 2025, 18:38Anastasia Conti: The European Hematology Association Congress Was Amazing
-
Jun 17, 2025, 17:07Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
-
Jun 17, 2025, 15:03Hamayak Sisakian Announces ESC Heart Failure Center Accreditation